TY - JOUR
T1 - Pushing the envelope in tissue engineering
T2 - Ex vivo production of thick vascularized cardiac extracellular matrix constructs
AU - Sarig, Udi
AU - Nguyen, Evelyne Bao Vi
AU - Wang, Yao
AU - Ting, Sherwin
AU - Bronshtein, Tomer
AU - Sarig, Hadar
AU - Dahan, Nitsan
AU - Gvirtz, Maskit
AU - Reuveny, Shaul
AU - Oh, Steve K.W.
AU - Scheper, Thomas
AU - Boey, Yin Chiang Freddy
AU - Venkatraman, Subbu S.
AU - Machluf, Marcelle
N1 - Publisher Copyright:
© 2015, Mary Ann Liebert, Inc. 2015.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Functional vascularization is a prerequisite for cardiac tissue engineering of constructs with physiological thicknesses. We previously reported the successful preservation of main vascular conduits in isolated thick acellular porcine cardiac ventricular ECM (pcECM). We now unveil this scaffold's potential in supporting human cardiomyocytes and promoting new blood vessel development ex vivo, providing long-term cell support in the construct bulk. A custom-designed perfusion bioreactor was developed to remodel such vascularization ex vivo, demonstrating, for the first time, functional angiogenesis in vitro with various stages of vessel maturation supporting up to 1.7? mm thick constructs. A robust methodology was developed to assess the pcECM maximal cell capacity, which resembled the human heart cell density. Taken together these results demonstrate feasibility of producing physiological-like constructs such as the thick pcECM suggested here as a prospective treatment for end-stage heart failure. Methodologies reported herein may also benefit other tissues, offering a valuable in vitro setting for "thick-tissue" engineering strategies toward large animal in vivo studies.
AB - Functional vascularization is a prerequisite for cardiac tissue engineering of constructs with physiological thicknesses. We previously reported the successful preservation of main vascular conduits in isolated thick acellular porcine cardiac ventricular ECM (pcECM). We now unveil this scaffold's potential in supporting human cardiomyocytes and promoting new blood vessel development ex vivo, providing long-term cell support in the construct bulk. A custom-designed perfusion bioreactor was developed to remodel such vascularization ex vivo, demonstrating, for the first time, functional angiogenesis in vitro with various stages of vessel maturation supporting up to 1.7? mm thick constructs. A robust methodology was developed to assess the pcECM maximal cell capacity, which resembled the human heart cell density. Taken together these results demonstrate feasibility of producing physiological-like constructs such as the thick pcECM suggested here as a prospective treatment for end-stage heart failure. Methodologies reported herein may also benefit other tissues, offering a valuable in vitro setting for "thick-tissue" engineering strategies toward large animal in vivo studies.
UR - http://www.scopus.com/inward/record.url?scp=84929485340&partnerID=8YFLogxK
U2 - 10.1089/ten.tea.2014.0477
DO - 10.1089/ten.tea.2014.0477
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 25602926
AN - SCOPUS:84929485340
SN - 1937-3341
VL - 21
SP - 1507
EP - 1519
JO - Tissue Engineering - Part A.
JF - Tissue Engineering - Part A.
IS - 9-10
ER -